Skip to main content
. 2016 Aug 5;7(40):66182–66191. doi: 10.18632/oncotarget.11097

Figure 3. Forest plots of relative risks of low-grade and high-grade hemorrhagic events in cancer patients treated with ramucirumab versus control.

Figure 3

A., relative risk of low-grade hemorrhagic events; B., relative risk of high-grade hemorrhagic events.